Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety evaluation of moxifloxacin-induced liver injury and its immune and genetic mechanisms
ChiCTR1800016966Phase 4Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jan 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of moxifloxacin in Infection (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoints: Alanine aminotransferase, Alkaline phosphatase and 2 more. Started Jan 2018; status: recruiting.
02
Drugs
moxifloxacin
03
Conditions
Infection
Beyond the preview
Go deeper on ChiCTR1800016966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016966.